UChicago receives $75M from AbbVie Foundation for construction of the cancer care and research pavilion

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

UChicago Medicine received a $75 million donation from the AbbVie Foundation, a nonprofit focused on advancing health equity, to help fund the construction of the new cancer care and research pavilion.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Technological innovations are often hailed as transformative tools capable of revolutionizing healthcare. From gene editing for conditions like sickle cell disease to AI predicting hospital readmissions, to telemedicine expanding healthcare access, these advancements have the potential to change the way we treat diseases. 
When Helene Brown, a cancer control pioneer who jokingly described herself as “the first in a long line of political oncologists,” delivered the keynote address at the Oncology Nursing Society annual meeting in 1990, she set forth bold predictions for the ensuing 20 years of the field: appointments conducted over “computerphone,” major genetic breakthroughs, and universal healthcare.
The definition of “therapeutic imperative” is this: A treatment necessity that must be met in order to prevent death. Once the imperative is clearly defined, addressing it properly links correct diagnosis with therapy and favorable prognosis. On the other hand, misdiagnosis or inadequate diagnosis fails to provide a framework for highly effective or curative therapy. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login